Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.57 - $0.99 $110,670 - $192,217
194,159 Added 523.68%
231,235 $191,000
Q1 2023

May 12, 2023

BUY
$0.51 - $0.78 $18,908 - $28,919
37,076 New
37,076 $22,000
Q2 2022

Aug 09, 2022

SELL
$0.71 - $2.43 $23,654 - $80,957
-33,316 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$2.31 - $5.13 $26,953 - $59,856
11,668 Added 53.9%
33,316 $79,000
Q4 2021

Feb 14, 2022

BUY
$4.45 - $8.09 $96,333 - $175,132
21,648 New
21,648 $103,000
Q3 2021

Nov 12, 2021

SELL
$6.94 - $8.85 $429,537 - $547,753
-61,893 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$7.45 - $16.27 $461,102 - $1.01 Million
61,893 New
61,893 $499,000
Q4 2020

Feb 03, 2021

SELL
$1.08 - $8.2 $328,331 - $2.49 Million
-304,011 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$0.95 - $1.42 $288,810 - $431,695
304,011 New
304,011 $356,000
Q3 2018

Nov 13, 2018

SELL
$1.38 - $1.94 $471,990 - $663,522
-342,022 Closed
0 $0
Q2 2018

Aug 09, 2018

BUY
$1.73 - $3.35 $591,698 - $1.15 Million
342,022 New
342,022 $592,000

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $393M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.